HomeComparePFGTF vs EQR

PFGTF vs EQR: Dividend Comparison 2026

PFGTF yields 2928.26% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFGTF wins by $361025539516.67M in total portfolio value
10 years
PFGTF
PFGTF
● Live price
2928.26%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$361025539516.72M
Annual income
$338,299,201,707,171,140.00
Full PFGTF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — PFGTF vs EQR

📍 PFGTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFGTFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFGTF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFGTF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFGTF
Annual income on $10K today (after 15% tax)
$248,901.90/yr
After 10yr DRIP, annual income (after tax)
$287,554,321,451,095,460.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, PFGTF beats the other by $287,554,321,451,090,800.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFGTF + EQR for your $10,000?

PFGTF: 50%EQR: 50%
100% EQR50/50100% PFGTF
Portfolio after 10yr
$180512769758.39M
Annual income
$169,149,600,853,588,320.00/yr
Blended yield
93.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PFGTF
No analyst data
Altman Z
-7.3
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFGTF buys
0
EQR buys
0
No recent congressional trades found for PFGTF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFGTFEQR
Forward yield2928.26%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$361025539516.72M$47.8K
Annual income after 10y$338,299,201,707,171,140.00$5,475.61
Total dividends collected$359452217273.28M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PFGTF vs EQR ($10,000, DRIP)

YearPFGTF PortfolioPFGTF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$303,526$292,825.77$11,380$679.82+$292.1KPFGTF
2$8,631,330$8,306,557.62$13,014$837.25+$8.62MPFGTF
3$229,995,057$220,759,533.40$14,961$1,036.20+$229.98MPFGTF
4$5,743,736,775$5,497,642,063.87$17,297$1,289.22+$5743.72MPFGTF
5$134,458,222,494$128,312,424,145.27$20,121$1,613.15+$134458.20MPFGTF
6$2,951,098,829,728$2,807,228,531,659.88$23,561$2,030.84+$2951098.81MPFGTF
7$60,740,157,648,354$57,582,481,900,544.34$27,783$2,573.54+$60740157.62MPFGTF
8$1,172,632,305,361,387$1,107,640,336,677,648.80$33,013$3,284.39+$1172632305.33MPFGTF
9$21,239,568,046,309,668$19,984,851,479,572,984.00$39,547$4,223.51+$21239568046.27MPFGTF
10$361,025,539,516,722,500$338,299,201,707,171,140.00$47,791$5,475.61+$361025539516.67MPFGTF

PFGTF vs EQR: Complete Analysis 2026

PFGTFStock

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, the company is developing Cxcolorectal, a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Full PFGTF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PFGTF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFGTF vs SCHDPFGTF vs JEPIPFGTF vs OPFGTF vs KOPFGTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.